GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gaush Meditech Ltd (HKSE:02407) » Definitions » ROE %

Gaush Meditech (HKSE:02407) ROE % : 3.51% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Gaush Meditech ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Gaush Meditech's annualized net income for the quarter that ended in Jun. 2024 was HK$61 Mil. Gaush Meditech's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was HK$1,748 Mil. Therefore, Gaush Meditech's annualized ROE % for the quarter that ended in Jun. 2024 was 3.51%.

The historical rank and industry rank for Gaush Meditech's ROE % or its related term are showing as below:

HKSE:02407' s ROE % Range Over the Past 10 Years
Min: -93.26   Med: 10.91   Max: Negative Equity
Current: 5.62

During the past 5 years, Gaush Meditech's highest ROE % was Negative Equity%. The lowest was -93.26%. And the median was 10.91%.

HKSE:02407's ROE % is ranked better than
63.09% of 802 companies
in the Medical Devices & Instruments industry
Industry Median: -0.145 vs HKSE:02407: 5.62

Gaush Meditech ROE % Historical Data

The historical data trend for Gaush Meditech's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gaush Meditech ROE % Chart

Gaush Meditech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
- Negative Equity - -93.26 10.91

Gaush Meditech Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Get a 7-Day Free Trial Premium Member Only - -167.17 14.27 7.54 3.51

Competitive Comparison of Gaush Meditech's ROE %

For the Medical Devices subindustry, Gaush Meditech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gaush Meditech's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's ROE % distribution charts can be found below:

* The bar in red indicates where Gaush Meditech's ROE % falls into.



Gaush Meditech ROE % Calculation

Gaush Meditech's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=189.796/( (1641.076+1838.059)/ 2 )
=189.796/1739.5675
=10.91 %

Gaush Meditech's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=61.306/( (1838.059+1658.488)/ 2 )
=61.306/1748.2735
=3.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


Gaush Meditech  (HKSE:02407) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=61.306/1748.2735
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(61.306 / 1382.356)*(1382.356 / 3066.543)*(3066.543 / 1748.2735)
=Net Margin %*Asset Turnover*Equity Multiplier
=4.43 %*0.4508*1.754
=ROA %*Equity Multiplier
=2 %*1.754
=3.51 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=61.306/1748.2735
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (61.306 / 125.73) * (125.73 / 159.608) * (159.608 / 1382.356) * (1382.356 / 3066.543) * (3066.543 / 1748.2735)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.4876 * 0.7877 * 11.55 % * 0.4508 * 1.754
=3.51 %

Note: The net income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Gaush Meditech ROE % Related Terms

Thank you for viewing the detailed overview of Gaush Meditech's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gaush Meditech Business Description

Traded in Other Exchanges
N/A
Address
No.11 Dongzhimen South Avenue, Room 1901, Building A, Zhonghui Plaza, Dongcheng District, Beijing, CHN
Gaush Meditech Ltd is a provider of a broad spectrum of ophthalmic medical devices. The segments of the company include 1) Proprietary products segment develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; 2) Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; 3) Technical services segment provides warranty services, maintenance services and after-sales services related consumables; and 4) Others segment.
Executives
Orbimed Advisors Iii Limited 2102 Investment manager
Orbimed Asia Gp Iii, L.p. 2102 Investment manager
Orbimed Asia Partners Iii, L.p. 2102 Investment manager
Gao Tieta 2201 Interest of corporation controlled by you
Gaush Holding Ltd 2101 Beneficial owner
Cuprite Gem Investments Ltd 2101 Beneficial owner
Warburg Pincus (bermuda) Private Equity Gp Ltd. 2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp Llc 2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp, L.p. 2201 Interest of corporation controlled by you
Warburg Pincus China-southeast Asia Ii (cayman), L.p. 2201 Interest of corporation controlled by you
Warburg Pincus Partners Ii (cayman), L.p. 2201 Interest of corporation controlled by you

Gaush Meditech Headlines

No Headlines